Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

NCT01533272 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

240

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: Tenofovir, emtricitabine, maraviroc
DRUG: Tenofovir, emtricitabine, lopinavir/r

Sponsor

Hospital Clinic of Barcelona